Announcement
N4 Pharma PLC : Positive Covid-19 In Vitro Study Results
RNS Number : 9549V
N4 Pharma PLC
12 August 2020
12 August 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Positive Covid-19 In Vitro Study Results
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that Nuvec® loaded with Coronavirus plasmid has successfully transfected Human Embryonic Kidney ("HEK") cells in vitro and induced an expression of the spike protein in the cells.
This successful result is the second stage of the Company's three stage plan for its Covid-19 proof of concept research project being undertaken with Evotec International Gmbh ("Evotec") means that the project will now move into its third stage, being the pre in vivo study to demonstrate expression of the spike protein in target cells in a murine target.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are delighted to have achieved in vitro transfection of HEK cells with Nuvec® loaded with coronavirus plasmid. We now move straight to the third stage of our Covid-19 project with our pre in vivo study at Evotec. The global pandemic continues to dominate all of our lives and we are extremely excited to be moving onto the next stage of our Covid-19 project, the successful outcome of which will determine our next work streams in this area and how we might collaborate with appropriate partners interested in any advantage our Nuvec® delivery system may provide. We look forward to providing updates on this project and our other work streams in due course."
Clarification note
In the Company's announcement of 16 April 2020, it stated the original intention to use murine peripheral blood mononuclear ("PBMC") cells for the in vitro study. However, when working with the PBMCs it was not possible to get a sufficient number to undertake all the experiments. As a result the in vitro work was done using HEK cells as detailed above.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
|
N4 Pharma plc |
|
|
Nigel Theobald, CEO |
Via Scott PR |
|
Luke Cairns, Executive Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Joint Broker |
|
|
Matthew Johnson/Caroline Rowe (Corporate Finance) |
|
|
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
|
|
|
|
|
Turner Pope Investments (TPI) Limited |
Tel: +44(0)20 3657 0050 |
|
Joint Broker |
|
|
Andy Thacker |
|
|
|
|
|
Scott PR |
|
|
Georgia Smith |
Tel: +44(0)1477 539 539 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
MSCSFIFEEESSELA
;